RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
10X Genomics Stock

10X Genomics Net Income 2025

10X Genomics Net Income

-81.84 M USD

Ticker

TXG

ISIN

US88025U1097

WKN

A2PPQJ

In 2025, 10X Genomics's profit amounted to -81.84 M USD, a -55.19% increase from the -182.63 M USD profit recorded in the previous year.

The 10X Genomics Net Income history

YEARNET INCOME (M USD)
2030e41.36
2029e14.6
2028e-12.17
2027e-74.62
2026e-115.42
2025e-81.84
2024-182.63
2023-255.1
2022-166
2021-58.2
2020-542.7
2019-31.3
2018-112.5
2017-18.8

10X Genomics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into 10X Genomics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by 10X Genomics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects 10X Genomics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of 10X Genomics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into 10X Genomics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing 10X Genomics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on 10X Genomics’s growth potential.

10X Genomics Revenue, EBIT and net profit per share

Date10X Genomics Revenue10X Genomics EBIT10X Genomics Net Income
2030e861.53 M undefined0 undefined41.36 M undefined
2029e741.74 M undefined-121.84 M undefined14.6 M undefined
2028e724.29 M undefined-86.09 M undefined-12.17 M undefined
2027e682.64 M undefined-75.48 M undefined-74.62 M undefined
2026e615.54 M undefined-128.04 M undefined-115.42 M undefined
2025e621.45 M undefined-81.01 M undefined-81.84 M undefined
2024610.79 M undefined-192.46 M undefined-182.63 M undefined
2023618.73 M undefined-194.95 M undefined-255.1 M undefined
2022516.4 M undefined-167.9 M undefined-166 M undefined
2021490.5 M undefined-52.3 M undefined-58.2 M undefined
2020298.8 M undefined-531.6 M undefined-542.7 M undefined
2019245.9 M undefined-30.6 M undefined-31.3 M undefined
2018146.3 M undefined-110.8 M undefined-112.5 M undefined
201771.1 M undefined-18.4 M undefined-18.8 M undefined

10X Genomics stock margins

The 10X Genomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of 10X Genomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for 10X Genomics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the 10X Genomics's sales revenue. A higher gross margin percentage indicates that the 10X Genomics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the 10X Genomics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the 10X Genomics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the 10X Genomics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the 10X Genomics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the 10X Genomics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

10X Genomics Margin History

10X Genomics Gross margin10X Genomics Profit margin10X Genomics EBIT margin10X Genomics Profit margin
2030e67.91 %0 %4.8 %
2029e67.91 %-16.43 %1.97 %
2028e67.91 %-11.89 %-1.68 %
2027e67.91 %-11.06 %-10.93 %
2026e67.91 %-20.8 %-18.75 %
2025e67.91 %-13.04 %-13.17 %
202467.91 %-31.51 %-29.9 %
202366.15 %-31.51 %-41.23 %
202276.68 %-32.51 %-32.15 %
202184.89 %-10.66 %-11.87 %
202080.46 %-177.91 %-181.63 %
201975.19 %-12.44 %-12.73 %
201880.45 %-75.73 %-76.9 %
201785.09 %-25.88 %-26.44 %

10X Genomics Aktienanalyse

What does 10X Genomics do?

10X Genomics is a US-based company specializing in the development of life science products. It was founded in 2012 by Serge Saxonov and Ben Hindson and is headquartered in Pleasanton, California. The company's business model focuses on providing technology platforms that enable researchers and scientists to analyze and understand complex biological data. It combines microfluidics, genomics, and bioinformatics. 10X Genomics is divided into different divisions, each focusing on different products and applications: Single-Cell Genomics, Long-Read Sequencing, Immune Profiling, and Spatial Transcriptomics. The company's products include the Chromium platform for cell type identification, disease research, and drug screening; Long-Read Sequencing technology for reading larger DNA fragments; tools and solutions for immune profiling and understanding the immune system; and Spatial Transcriptomics technology for studying the spatial organization of gene expression in tissues. 10X Genomics also offers other products and solutions in the field of genomic sequencing and analysis, including DNA preparation and sequencing kits, software for DNA data analysis and interpretation, and consulting and training services. The company has received various awards and recognition for its innovative approach, including the Innovation Award from The Scientist magazine and the Disruptive Technology Award from the Wall Street Journal. Overall, 10X Genomics has become a leading company in the life science industry, contributing to the advancement of scientific understanding and supporting progress in medicine and biotechnology. 10X Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding 10X Genomics's Profit Margins

The profit margins of 10X Genomics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of 10X Genomics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating 10X Genomics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

10X Genomics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When 10X Genomics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about 10X Genomics stock

How much profit has 10X Genomics made this year?

10X Genomics has made -81.84 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -55.19% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does 10X Genomics publish its earnings?

10X Genomics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of 10X Genomics?

The profits of 10X Genomics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of 10X Genomics?

You can learn more about the earnings of 10X Genomics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does 10X Genomics pay?

Over the past 12 months, 10X Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, 10X Genomics is expected to pay a dividend of 0 USD.

What is the dividend yield of 10X Genomics?

The current dividend yield of 10X Genomics is .

When does 10X Genomics pay dividends?

10X Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of 10X Genomics?

10X Genomics paid dividends every year for the past 0 years.

What is the dividend of 10X Genomics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is 10X Genomics located?

10X Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von 10X Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of 10X Genomics from 9/1/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/1/2025.

When did 10X Genomics pay the last dividend?

The last dividend was paid out on 9/1/2025.

What was the dividend of 10X Genomics in the year 2024?

In the year 2024, 10X Genomics distributed 0 USD as dividends.

In which currency does 10X Genomics pay out the dividend?

The dividends of 10X Genomics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von 10X Genomics

Our stock analysis for 10X Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 10X Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.